April 26 (Reuters) - CG Oncology Inc CGON.O:
CG ONCOLOGY ANNOUNCES BEST-IN-DISEASE DURABILITY DATA IN BOND-003 COHORT C AND PROMISING EARLY SIGNAL IN COHORT P FOR CRETOSTIMOGENE GRENADENOREPVEC AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING
CG ONCOLOGY INC - CRETOSTIMOGENE MONOTHERAPY SHOWS 42.3% RESPONSE RATE AT 24 MONTHS
CG ONCOLOGY INC - 58.3% PATIENTS SHOW DURABLE RESPONSE AT 24 MONTHS
CG ONCOLOGY INC - 97.3% PATIENTS FREE FROM MIBC PROGRESSION AT 24 MONTHS
CG ONCOLOGY INC - 91.6% RESPONDERS CYSTECTOMY-FREE AT 24 MONTHS
CG ONCOLOGY INC - NO GRADE 3 OR GREATER ADVERSE EVENTS REPORTED
Source text: ID:nGNX7DLCJh
Further company coverage: CGON.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.